Clinical report on Kanglaite Injection (KLT) in improving cancer patients’ quality of life

LU-Xia
The Second Department of Internal Medicine, Jiangxi Provincial Tumor Hospital, Jiangxi, Nanchang 330029, China

[ABSTRACT] **Purpose** To apply Kanglaite Injection to advanced cancer patients with the purpose of enhancing patients’ QOL and prolong survival. **Method** KLT 100~200ml, iv drip, one time/day, 20 days as a treatment course. **Result** 27.8% (5/18) of patients got complete response on cancerous pain and 50% (9/18) got partial response. Total response rate was 77.8% (14/18). 73.5% (25/34) of patients got their QOL enhanced. **Conclusion** KLT has effects on palliative treatment of advanced cancer patients.

[KEY WORDS] Tumor / drug treatment; Injection; Anticancer drug (TCM) / treatment application; Quality of life; KLT


Palliative treatment to advanced cancer patients is a worldwide issue. The cure rate in developed countries is 45%~50% \[1\]. While in China it is only 10%. To find a method or drug that can control symptoms of advanced cancer patients and enhance their quality of life has become a worldwide focus. I adopted Kanglaite Injection provided by Zhejiang Kanglaite Pharmaceutical Co., Ltd. in my trial and got desirable results.

1. **Material and method**
   1.1 **General data**
   In our group of advanced cancer patients: 34 cases in all, male 23 cases, female 11 cases; age 26~71; median age 51. Cancer type: lung cancer 17 cases, stomach cancer 4 cases, colon-rectal cancer 4 cases, liver cancer 4 cases, others 5 cases. 18 cases had pain caused by metastasis: chest pain 8 cases, abdomen pain 5 cases, waist-back pain 4 cases, limbs pain 1 case. Pain degree: moderate 13 cases, severe 5 cases. KPS score: 30 marks/1 case, 40 marks/4 cases, 50 marks/4 cases, 60 marks/8 cases, 70 marks/9 cases, 80 marks/8 cases.

   1.2 **Treatment method**
   KLT provided by Zhejiang Kanglaite Pharmaceutical Co., Ltd., 100-200ml, iv drip, one time/day, 20 days as a treatment course.

2. **Result**
2.1 Pain relief
To evaluate according to WHO pain degree \[2\]: 1~3 marks as mild pain, 4~7 marks as moderate pain, 8~10 as severe pain. After one course of treatment, 5 out of 13 cases with moderate pain had their pain disappeared, 5 relieved to mild pain, and 3 no change. 4 out of 5 cases with severe pain had relieved to moderate, and 1 had no observable change. CR 27.8% (5/18), PR 50% (9/18), total RR 77.8% (14/18).

2.2 QOL improvement
Based on criterion for Karnofsky QOL evaluation \[3\], among 34 cases: 9 cases no change (26.5%), 9 cases increased by 10 marks (26.5%), 8 cases increased by 20 marks (23.5%), 4 cases increased by 30 marks (11.8%), 4 cases increased by 40 marks (11.8%, 4/34).

2.3 Toxic & side effects
No adverse reactions like cardiac, hepatic or renal dysfunction. No skin rash. 5 cases had slight phlebitis and 1 cases had chill and fever that were self relieved one day later.

3. Discussion
With the development in tumor treatment methods, most tumor patients get benefits from clinical treatment. More attention is increasingly given to the QOL improvement. Cachexia is the major complication among advanced cancer patients. Cancerous pain is one of the commonly symptoms that is hardest to bear and more fearful than death itself. Currently, the normal anticancer treatment (surgery operation, radiotherapy, chemotherapy) often aggravates the occurrence and development of cachexia so that break off the normal treatment. Corticosteroid can stimulate appetite though, it cannot increase weight. Indomethacin can relieve the general condition of cachexia except survival prolonging \[4\]. KLT has remarkable actions of tumor cell inhibition and anti metastasis on liver cancer and lung cancer, etc. Besides, KLT can enhance overall body immunity, strengthen effects of radio- and chemo-therapy, reduce toxicity, relieve pain, fight cachexia, and promote quality of life. As an intravenous lipid emulsion, KLT provide high energy nutrition to the body with no observable toxicity or side effects to the normal body cells and tissues.

The trial, headed by Prof. Li Tongdu, on KLT treating 376 cases of advanced cancer patients had showed that the total RR of KLT to cancerous pain was up to 80.4% and there was desirable effects on QOL improvement. 92.1% of patients got their KPS score increased, 91.7% of patients got QOL improved, and 42.3% of patients gain in weight. Meanwhile, the peripheral leukocytes of most patients were raised to normal level after KLT treatment \[2\]. The trial in our group had similar outcome. KLT is, therefore, further proved to be an desirable iv preparation for advanced cancer treatment, especially for advanced palliative treatment.
References

(End)